IL17A and metabolic dysfunction-associated steatohepatitis: It was suggested that FGF21 exerts anti-inflammatory and anti-carcinogenic effects by inhibiting hepatocyte TLR4-IL-17A signaling in the NASH-HCC mouse model, which may prevent the development of HCC.